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Abstract 
Background: High quality clinical samples are critical for meaningful interpretation of data obtained in both basic 
and translational medicine. More specifically, optimized pre-analysis handling to bio-sample is crucial for avoiding 
biased analysis in a clinical setting. A universally applicable method for the evaluation of sample quality and pre-anal-
ysis handling is therefore in great demand.
Methods: The fingerprint pattern of low molecular weight (LMW) peptides in sera is directly associated with sample 
quality and handling process. Previous studies for enrichment/isolation of LMW peptides have shown that LMW 
peptides can be enriched by silica meso-porous material in a sensitive and high-throughput manner. Here, a peptide 
profile approach utilizing mesoporous silica chip-based sample preparation combined with MALDI MS analysis was 
used as a new platform for evaluation of bio-sample quality. Rat sera were selected as model sample and analyzed 
according to their LMW peptide fingerprint spectra.
Results: This novel method can complete the entire sample preparation procedure in a short period of time 
(<40 min), requires minimum amounts of sample (<10 µL), is of high sensitivity (LOD 10 ng/mL) as well as high 
reproducibility (CV% < 15%). According to the acquired LMW peptide spectra, we were able to distinguish the serum 
samples processed under different conditions (including different storage temperature, time, and freezing/thaw 
cycles) with the help of bioinformatics tools (principle composition analysis and significant difference analysis), and 
identify the samples that had significantly changed due to the inappropriate processing. Based on the percentage of 
significantly changed peaks in LMW peptide mass spectrum after handling, a judgment standard was established that 
can be used to evaluate the status of preservation of a biological sample. In addition, our principle study established 
recommendations for storage time, storage temperature and freeze/thaw conditions.
Conclusion: Our novel method for analysis of bio-samples allows for effective identification of variations in composi-
tion within samples, and provides a cost-effective tool for simple sample manipulation in a clinical setting.
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Background
Both basic and translational medical researches depend 
on the availability of high quality clinical samples, which 
often have to be processed and analyzed in a high-
throughput manner [1]. A major issue for biomarker 
studies, serum samples often become unstable during the 
collection and storage process, resulting in poor repro-
ducibility. Because of this, few biomarkers proposed 
have actually been translated into the clinical practice 
[2–4]. Serum is a highly dynamic biological sample, and 
contains various degradative enzymes such as proteases. 
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They can be released from activated, dying, or lysed neu-
trophils or mononuclear phagocytes during sample pro-
cess [5]. Inevitably, these enzymes will hydrolyze serum 
proteins and peptides, and as a consequence change the 
proteomic pattern of the sample. In addition, other pro-
cesses such as protein/peptide precipitation, aggregation 
or adsorption can also greatly alter the proteome compo-
sition of serum [1]. These alterations are likely influenced 
by handling conditions, including clotting procedure, 
storage time, storage temperature and freeze/thaw cycles 
and other factors [2]. Thus, evaluation of the changes of 
serum composition and optimization of the sample han-
dling procedure for minimizing the pre-analysis variabil-
ity are of paramount importance for clinical research.
Ideally, every sample collected for clinical research 
should be tested or monitored during the entire pro-
cess of collection, storage, and experimental handling 
to ensure the highest possible sample quality. Consider-
ing the large number of specimens commonly involved 
in clinical tests, the testing methods used should ideally 
be fast, consume little sample volume, compatible with 
high-throughput technology, available for easy manipula-
tion, and cost-effective; besides, the results of the sample 
analysis should reflect the changes that have occurred in 
the sample since collection.
Various methods have been developed and applied to 
assess the quality of clinical sera and to evaluate sampling 
procedures, including enzyme-linked immunosorbent 
assay (ELISA) [6, 7], capillary electrophoresis (CE) [8], 
2-D or 1-D polyacrylamide gel-electrophoresis (PAGE) 
[1, 9, 10], antibody microarray chip [10], aptamer micro-
array array [11], and novel mass spectrometry technolo-
gies such as the surface-enhanced (SELDI-) [12–14] and 
matrix-assisted laser desorption/ionization time of-flight 
(MALDI-TOF) MS [2, 3, 15–19]. However, there remains 
a lack of quality-controlling platforms for large-scale 
analysis of clinical specimen. For instance, ELISA [6, 7] 
and CE [8] only monitor alterations of one or few pro-
teins, and they do not necessarily reflect variations in 
sample composition in a comprehensive manner. Fur-
thermore, PAGE profiling has been to be resistant and 
insensitive to certain changes due to long-term storage 
and freeze/thaw cycling [1, 10, 20]. The extensive appli-
cation of microarray technology for quality control in 
clinical bio-banks is limited by antibodies commercially 
available, as well as by the high costs associated. SELDI- 
and MALDI-TOF MS offer great potential for proteome 
profiling, and have become promising tools for the con-
trol of serum quality and assessment of sample han-
dling artifacts. For MS-based protein profiling of clinical 
samples, commonly used preparation methods are C4/
C18 zip-tip resin [2, 15], C8/C18-derivatized magnetic 
beads [3, 16–19, 21], or anion-exchange chromatography 
purification [12]. However, these methods are labor- 
and time-intensive due to the labor-intensive proce-
dures involved, including repeated centrifugation steps, 
multiple steps of sample transfer, washing and elution, 
and are therefore of limited use in the clinical settings, 
where sample numbers usually reach several hundreds or 
even more. More importantly, highly abundant proteins 
with large molecular weight (>10  kD, i.e. albumins and 
globulins) are often over-represented in samples, which 
in methods without appropriate selection procedures 
results in under-representation of low-weight peptides 
or proteins. Thus, a universal method is still required to 
ensure high sample quality and optimal pre-analysis han-
dling, for instance, appropriate sample preparation and 
applicable to extensive clinical practices.
Selection of an appropriate target is crucial for mean-
ingful monitoring of serum sample quality, as it is dif-
ficult to test every compound in complex bio-fluids. 
Low molecular weight (LMW) peptides are important 
resource for disease biomarkers [22–26]. Meanwhile, 
LMW fraction varies during the sample handling due to 
the appearance of new peptides that are generated from 
the hydrolysis of large proteins [18]. Therefore, LMW 
peptide profiles should be informative about changes in 
sample composition. Here, we aim to develop a novel 
approach that is based on the LMW peptide profile for 
the evaluation of sample quality and handling procedure.
Nano-materials with novel physicochemical properties 
have been widely used in the area of biomedical research. 
Mesoporous silica materials (MPSM) are known to take 
up peptide molecules below certain molecular weights 
with great efficiency, thanks to their ability to sieve mol-
ecules of different sizes. These captured peptides can 
then be eluted conveniently from the mesoporous silica 
[22–28]. In addition, it has also been shown that peptides 
stored in the pores of MPSM exhibit greater stability dur-
ing long-term storage [28]. Therefore, methods based on 
MPSF should provide an ideal platform for the enrich-
ment of LMW peptides in clinical samples. Subsequently, 
these samples can then be analyzed by mass spectrome-
try to profile the LMW peptides, producing a fingerprint 
spectrum, which should offer crucial information about 
the sample composition and its variability.
In this report, we describe the mesoporous-material 
based MALDI MS approach as a novel tool to assess the 
quality of clinical specimens, and also to evaluate the 
handling procedure. We performed a systematic analysis 
of rat serum to investigate the influence of several pre-
analytical factors (including storage temperature, storage 
time and freeze/thaw cycles) on serum LMW peptide. 
We analyzed hundreds of samples using a high-through-
put procedure in a very short time with little sample 
consumption, high sensitivity and good reproducibility. 
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Employing bioinformatics tools such as principle compo-
sition analysis (PCA) and significant difference analysis, 
the alterations of samples handled under different con-
ditions can be effectively recognized, and the extent of 
change of LMW peptide pattern is highly related to han-
dling condition, proving the effectivity of this approach 
as an evaluation tool. Based on this study, we offer some 
simple recommendations to avoid or correct systematic 
bias generated from the sample handling procedure.
Experiments and materials
Chemicals
Trifluoroacetic acid (TFA), acetonitrile (CAN, HPLC 
grade), α-cyano-4-hydroxycinnamic acid (CHCA), syn-
thesized standard peptides (Mw 1338) and the Grace Bio-
Labs reusable CultureWell (TM) gaskets were purchased 
from Sigma-Aldrich (St. Louis, Mo, USA).
Sample preparation with mesoporous silicon wafer
The mesoporous silicon wafer was prepared according to 
previously published methods [22–28]. The type of the 
mesoporous silicon wafer we used was L121 [28], which 
is a silica material that exhibits large porosity (~55%), with 
an average pore size of 5.2  nm. The L121 mesoporous 
silicon wafer could completely exclude proteins over 
29,000  Da such as albumin, and help to significantly 
increase MS sensitivity of peptides below 3500 Da [28].
Serum samples were prepared according to a previ-
ously published procedure [23]. The fresh chips were 
firstly pre-baked overnight in an oven at 120  °C. After-
wards, cultureWell(TM) gaskets were cleaned with 100% 
ethanol and pressed on the chip surface with forceps to 
ensure a complete seal with chip. Then 6  μL of serum 
sample was pipetted into each 3 mm well, and incubated 
for 20  min in a humidified chamber at room tempera-
ture. Then the serum was pipetted up from wells and dis-
card. To wash away the large proteins, 10 μL of deionized 
water (DI water) was pipetted into each well and then 
discard directly. The washing step was repeated 4 times. 
Finally, 6 μL elution buffer (0.1% TFA + 50% ACN) was 
pipetted to each sample well, incubated in a humidified 
chamber at room temperature for 90 s, and pipetted out 
ready to perform MALDI-TOF analysis. The acidic elu-
tion buffer could ionize the captured peptides in silicon 
pores and then efficiently resolved these peptides from 
pores. Meanwhile, the constitution of elution buffer 
(0.1% TFA + 50% ACN + 50% DI water) made it possible 
to directly apply eluted peptide solution on MALDI MS 
target plate [22–28].
Mass spectrometry
Firstly, 1  μL chip-processed sample was spotted on the 
MALDI target plate and air-dried. Then 1  μL matrix 
(α-cyano-4-hydroxycinnamic acid (CHCA), 5  g/L) in 
50% acetonitrile containing 0.1% TFA was spotted on 
the dried sample spot and allowed to co-crystallize. Mass 
spectra were acquired using a SHIMADZU AXIMA Res-
onance MALDI-IT-TOF equipped with a nitrogen laser 
emitting light at 337 nm, with an adjustable mass range 
of 800–4000  Da. The positive ion was detected under 
reflective mode. The spectrums of 500 laser shots were 
typically averaged to produce the final sample spectrum. 
The optimized accelerating voltage used was 50 kV. Data 
acquisition was controlled automatically by Shimadzu 
Biotech Launchpad program to deplete artifact bias.
Rat serum handling procedure
Blood was collected from the eyes: elaborate of grown-up 
rats cultivated normally. All blood samples were main-
tained at room temperature (~25 °C) for 1 h to allow sam-
ple coagulation and then centrifuged at 4 °C for 15 min at 
1400×g. The serum layer was aspirated and collected in 
polypropylene tubes to avoid the fluid in the buffy-coat 
layer. Samples were then aliquoted and stored at different 
storage conditions, except for the samples immediately 
analyzed.
Short‑term storage
Fresh serum aliquots were stored either in an ice bath 
(0–4 °C) or at room temperature (25 °C). Samples stored 
first for 4, 8, 12, 24  h were analyzed at the indicated 
times.
Long‑term storage
Fresh serum aliquots were stored either at room temper-
ature (25  °C), at 4  °C, at −20 °C, at −80 °C, or in liquid 
nitrogen (−190  °C). At the appropriate times, aliquots 
were thawed at 4  °C, and subsequently prepared for 
analysis.
Freeze/thaw cycles
Four different freeze/thaw conditions were tested: 
−190 °C/25 °C, −190 °C/4 °C, −80 °C/25 °C, or −80 °C/4 °C. 
The serum samples were frozen down and kept at the 
indicated temperatures for 2  h, and then thawed at the 
indicated temperatures for 1  h and then immediately 
refrozen. This procedure was repeated for 1–5 times, 
amounting to 20 different freeze/thaw cycle conditions.
Data processing and multivariate statistical analysis
Mass spectrometry data were converted into ASCII 
format on the integrated software of the SHIMDZU 
MALDI-TOF instrument (Shimadzu Biotech Launch-
pad). PCA analysis and significant difference analysis 
were performed on the commercially available program 
MarkerView version 1.2.1 version (AB SCIEX). PCA 
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analysis was conducted using a non-supervised model, 
and for the scaling procedure we used a Pareto method.
Results and discussion
Performance of mesoporous chip as enrichment platform 
of LMW peptides in serum
In order to evaluate the sensitivity of the MS approach 
based on mesoporous chip enrichment, we tested serum 
samples spiked with synthesized standard peptide (Mw 
1338) in different concentrations. As illustrated in Fig. 1, 
a strong signal for the standard peptide at m/z 1339 was 
detected at the concentrations tested. This standard peak 
was resolved from the background even at a concentra-
tion as low as 10 ng/mL. A good linear correlation with 
R2 = 0.996 was obtained in the range of 10–500 ng/mL, 
as shown in Fig.  2. These results confirmed the good 
performances of mesoporous chip-enabled MALDI MS 
approach in the relative quantitative analysis. Repeated 
test of one same serum sample in the different well on the 
mesoporous chip also showed good reproducibility, and 
the CV% of five endogenous m/z peaks from the peptide 
MS pattern respectively are 12.6% (m/z 1561.41), 6.6% 
(m/z 1553.37), 10.6% (m/z 1552.39), 5.8% (m/z 1394.66), 
9.0% (m/z 897.62).
The performance of mesoporous silica chip to elimi-
nate abundant large proteins has been detailed studied 
[22–28]. These works demonstrated that diverse LMW 
peptides (PI 4.0–10.2, molecular weight 800–4000  Da) 
could be stably harvested on the mesoporous silica chip 
[22, 28], and the abundant large proteins were efficiently 
eliminated [22–28]. Therefore, it is possible to apply this 
platform to sensitively acquire LMW peptide MS-pattern 
of bio-samples, and further estimate the variation of the 
different samples according to the MS pattern.
In our experiments, the whole sample preparation pro-
cedure was finished in 40 min in a high-throughput man-
ner, with a very simple manipulation without repeated 
centrifugation, multiple fluid transfer, or column puri-
fication. This procedure significantly reduced the sam-
ple and labor consumption and increased the analysis 
throughput, therefore, should be suitable for the analy-
sis of large number of samples, which should enable this 
method universally applicable in frontline clinical organi-
zations such as hospital and bio-bank.
Impact of long‑term storage condition on sample quality
It has been proven that the storage temperature exerts 
remarkable effects on the composition of bio-specimen 
stored for long-term [1, 19]. To verify if the peptide pro-
filing enabled by meso-porous chip could express the 
effect caused by the stored temperature, we selected the 
fresh serum that just delivered from the living body as 
the standard specimen, and compared the MS patterns of 
samples stored under different environments. Five com-
mon storage environments were compared, including 
refrigerator cold closet (4 °C), refrigerator freezing cham-
ber (−20 °C), ultra-low temperature freezer (−80 °C), liq-
uid nitrogen (−190 °C) and at room temperature (25 °C).
After 9  day storage, obvious changes were observed 
directly in the MS spectra of the serums at 25  °C 
(Fig.  3). A more distinct differentiation was illustrated 
in PCA analysis (Fig. 4). The 25 °C samples was the most 
Fig. 1 MALDI MS spectra of serums spiked with standard peptide (m/z 1339) at different concentrations (0, 10, 75, 100, 250, 500 ng/mL)
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distinctive group, far away from the samples stored at 
other temperatures. Meanwhile, the 4  °C group also 
showed a complete separation from the fresh samples, 
indicating that the 4 °C is also a destructive condition for 
the long-term storage. Comparatively, the MS patterns 
from −20, −80, and −190 °C groups are much closer or 
even overlapped to the fresh serum group, suggesting the 
key effect of freezing for the sample long-term storage. 
Lower temperature showed better conservation effects, 
as can be seen in −80 and −190 °C group, which just par-
tially separated from the fresh group. 
To further investigate the extent of variation of samples 
at different conditions, we calculated the number of m/z 
peaks that indicated significant difference between stored 
samples and fresh samples (judgment standard: p value 
<0.01). As the temperatures rise, the percentage of peaks 
exhibiting significant difference (named as Psd value) 
also increased dramatically (Fig.  5): the Psd values of 
−190, −80, −20, 4 and 25 °C groups were 15, 15, 35, 85, 
and 95% respectively, which was coincide with the results 
of PCA analysis.
This trend was further demonstrated from the analy-
sis of samples stored for 48 days. The obvious changes of 
spectra can even be distinguished directly at the temper-
ature of 4 and −20 °C (Fig. 6). In the PCA analysis, all the 
sample groups separated completely from the fresh sam-
ples except for the −190 °C group (Fig. 7), and the general 
freezing condition such as −20 °C is no longer appropri-
ate. Besides, after stored for 48 day, the percentage of m/z 
peaks showing significant difference enhanced obviously 
compared with the samples stored 9 day, and still showed 
the highly dependent on temperatures (Fig.  5). To our 
surprise, the sample stored in ultra-low temperature 
freezer (−80 °C) also showed significant difference from 
the fresh samples and the Psd value reached 40%, which 
probably should be attributed to unstable temperature 
due to the frequent opening of the freezer door during 
this long period. These results suggested that as the stor-
age time prolonged, a temperature-lowered and more 
stable condition is required.
It has been widely discussed that the proteases 
remained in bio-samples remarkably varied the proteome 
profile, especially at the enzyme-activated temperature 
[5, 29]. Besides, other influence factors such as the bacte-
rial contaminate also emerge at relatively high tempera-
ture as time passes [29]. Thus, the storage temperature 
crucially influences the quality of long-term storage sam-
ples. We have discovered that the LMW peptide profiles 
Fig. 2 Linear correlation of MS intensities with peptide concentra-
tions in the range from 10 to 500 ng/mL
Fig. 3 MALDI MS spectra of serums stored at different temperatures (−190, −80, −20, 4 and 25 °C) for 9 days and fresh collected serum
Page 6 of 10Liang et al. Clin Proteom  (2016) 13:34 
enabled by the meso-porous chip were able to effectively 
represent the differentiation of samples stored at differ-
ent temperatures, and the extent of variation of peptide 
spectra highly correlated with temperature, implying that 
this proposed approach can be utilized to evaluate the 
variation of sample quality caused by the handling proce-
dure. The samples frozen at below −80 °C were custom-
arily considered as stable and conserved samples. Based 
on the above analysis, it is concluded that in this chip-
enabled measurement, the serum with a Psd value lower 
than 40% can be seen as a well preserved sample. From 
our experiments, liquid nitrogen should be the most ideal 
storage environment for the long-term storage of serum 
samples, and ultra-low temperature freezer could also be 
employed under the condition of temperature stabilized.
Impact of short‑term storage conditions on sample quality
Clinical specimen just collected may not be able to be 
conserved in liquid nitrogen or freezer at the first time 
due to the lack of related instruments at the clinical 
frontlines, and it is probably inevitable to store samples at 
room temperature (25 °C) or ice bath (~0 °C) for a short 
while (<24 h). In order to optimize the short-term stor-
age conditions, we analyzed the LMW peptide pattern of 
serums stored under these two temperatures for differ-
ent times. As can be seen in PCA analysis (Fig. 8), at the 
both two temperatures, the alteration of peptide profiles 
enhanced as the storage time increase; meanwhile, the 
differentiation of 25 °C group (Fig. 8a) from fresh serum is 
much more evident than the 0 °C group (Fig. 8b). This is a 
theoretically reasonable result: the ice bath is a preferable 
storage condition compared with the room temperature 
due to the inactive enzyme and depressed hydrolyzing 
Fig. 4 Principle composition analysis (PCA) of the different tempera-
tures (−190, −80, −20, 4 and 25 °C) stored serums for 9 days
Fig. 5 The percentage of peaks experienced significant difference at 
different temperatures (−190, −80, −20, 4 and 25 °C) for 9 days (black 
square) and 48 days (white circle)
Fig. 6 MALDI MS spectra of serums stored at different temperatures (−190, −80, −20, 4 and 25 °C) for 48 days and fresh collected serum
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effect at lower temperature. A more clear results were 
showed by comparing the percentage of peaks indicating 
significant difference (Psd value), which increased gradu-
ally as the time passed under the both two temperature 
(Fig.  9). The Psd value was still lower than 11% (10.7%) 
even stored for 24 h at 0 °C, yet it was already over 60% 
when stored for 8 h at 25 °C. These results suggested that 
the best way to store serum for a short time is around 
0 °C, and if the condition is unavailable, the time stored at 
room temperature should not be longer than 8 h.
Impact of freeze/thaw cycles on sample quality
Another important pre-analysis factor influencing the 
quality of samples is freeze/thaw handling, which is 
generally inevitable during from sample collecting to 
usage. It had been advised that freeze/thaw cycle altered 
the proteomics of serum [1]. To reduce this alteration, 
mesoporous chip-MS approach was used to investigate 
the serum cohort froze/thawed at different temperature 
conditions, including two common freezing-tempera-
tures (−190 and 80  °C) and two thawing-temperatures 
(4 and 25  °C). As shown in Fig.  10, after 2 freeze/thaw 
cycles, the serums frozen at −80 °C exhibited lower Psd 
values compared with the condition of −190  °C. Mean-
while, the serums thawed at 4 °C showed lower Psd val-
ues than 25  °C. Among the four freeze/thaw conditions 
tested here (Fig.  10), the best conservation of serums 
with lowest Psd value was the condition of freezing at 
−80 °C/thaw at 4 °C. Similar results were observed after 3 
cycles of freeze/thaw handling (Fig. 10).
It had been reported that freeze/thaw handling 
altered the composition of serum mainly due to the 
protein/peptide aggregation, precipitation and adsorp-
tion to tube-wall during this procedure [1]. Thus, it 
can be deduced that the over-fast freezing at −190  °C 
highly increases the aggregation and precipitation 
of proteins (peptide), changing more composition of 
Fig. 7 PCA of the serums stored at different temperatures (−190, 
−80, −20, 4 and 25 °C) for 48 days
Fig. 8 PCA of the serums stored under 25 °C (a) and 0 °C (b) for dif-
ferent times (0, 4, 8, 12, and 24 h)
Fig. 9 The percentage of peaks experienced significant difference 
in serums stored for different times (4, 8, 12, and 24 h) at 25 °C (white 
circle) and 0 °C (black square)
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serum than −80 °C. On the other hand, fast thawing at 
25 °C activates the enzymes in serum, resulting in more 
hydrolysis to the serum proteome than 4 °C. Thus, slow 
freezing at −80 °C and thaw at 4 °C should be selected 
during the storage and test of serum, to obtain a best 
conservation to the protein/peptides. Considering the 
liquid nitrogen is still the optimized environment for 
the long-term storage as we proved above, it is rec-
ommended that the bio-fluid could be frozen firstly at 
−80 °C, and then transferred to liquid nitrogen for the 
long-term storage.
Afterwards, we further investigated the impact of 
freezing frequency. Serums were repeatedly froze at 
−80 °C and then thawed at 4 °C for 1–5 cycles, and then 
compared with the original fresh serums. As shown in 
PCA analysis (Fig.  11), when the cycles of freezing/
thaw were lower than three times, the frozen/thawed 
serums were hard to discern from fresh serums. When 
the freezing/thaw cycles exceeded 4 times, the frozen/
thawed serums were separated from the fresh serums 
completely (Fig. 11). The same trends can also be con-
cluded from the comparison of Psd values (Fig.  12). 
The Psd values were almost constant and only around 
20% when freezing times were less than 3. However, as 
freezing times increased to 5, the Psd value was over 
40%, implying a serious change of serum proteome 
(Fig. 12).
Proteins in serum tended to aggregate and participate 
during freezing procedure [1]. These aggregations of pro-
teins were getting hard to re-dissolve after serums were 
repeatedly frozen and thawed, resulting in the change 
of serum proteome. Therefore, to preserve the original 
constituents in serum, the freezing/thaw handling to 
serum should be as few as possible. As we studied, for 
the serums used for proteomics research, freezing/thaw 
cycles shouldn’t be over three times.
Conclusions
In summary, through the mesoporous material assisted 
MALDI MS approach, we have successfully measured the 
alteration of LMW peptides in serums caused by different 
handling condition, and identified the sample groups that is 
handled under inappropriate conditions and no longer suit-
able for further clinical experiments. This indicates that the 
method presented here does offer the critical information 
on sample composition that is highly related to the handling 
procedure. On the basis of these findings, we propose that 
this method can be used as an effective evaluation tool for 
the controlling of sample quality. More importantly, this 
simple and fast method should be particularly useful to a 
wide application in clinical settings, where quality tests for a 
large amount of samples before clinical practices are in great 
demand. Besides the serum samples, this approach should 
be extendable to the evaluation of other fluid bio-samples 
Fig. 10 The percentage of peaks exhibiting significant difference in 
serums frozen/thawed at different temperatures for 2 and 3 cycles
Fig. 11 PCA of serums froze at −80 °C and then thawed at 4 °C for 
1–5 cycles
Fig. 12 The percentage of peaks exhibiting significant difference in 
serums frozen at −80 °C and then thawed at 4 °C for 1–5 cycles
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containing peptides, such as urea, saliva or cerebrospinal 
fluid.
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